Maravai LifeSciences Announces Pricing of an Upsized Secondary Offering of Class A Common Stock by Selling Stockholders

Rhea-AI Summary

Maravai LifeSciences Holdings, Inc. (MRVI) announced an upsized public offering of 18,000,000 shares of Class A common stock at a price of $31.25 per share. This offering, increased by 3,000,000 shares from previous announcements, includes a 30-day option for underwriters to purchase an additional 2,700,000 shares. The offering is set to close on April 12, 2021. Notably, Maravai will not receive proceeds from this sale, which is managed by firms including Morgan Stanley, Jefferies, and Goldman Sachs.

Positive

• Upsized public offering of 18,000,000 shares increases visibility in the market.
• Involvement of major underwriters like Morgan Stanley and Goldman Sachs enhances credibility.

Negative

• Maravai will not receive any proceeds from the offering, limiting potential revenue growth.
• Dependence on selling stockholders may signal lack of confidence in the company's financial health.

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of an upsized public offering of 18,000,000 shares of Maravai’s Class A common stock by certain selling stockholders that was previously announced, at a public offering price of $31.25 per share. The offering was upsized by 3,000,000 shares of Maravai’s Class A common stock from what was previously announced. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of Maravai’s Class A common stock, which was upsized from 2,250,000 shares of Maravai’s Class A common stock. The offering is expected to close on April 12, 2021, subject to customary closing conditions.

Maravai will not receive any proceeds from the sale of shares by the selling stockholders.

Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel and KeyBanc Capital Markets are also acting as joint book-running managers, and Academy Securities, Loop Capital Markets, Penserra Securities LLC and Tigress Financial Partners are acting as co-managers for the offering.

The offering is being made only by means of a prospectus, copies of which may be obtained from: Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526, by facsimile at 212-902-9316 or by email at prospectus-ny@ny.email.gs.com.

A registration statement relating to the sale of these securities has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”) on April 5, 2021. Copies of the registration statement can be accessed by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

Note Regarding Forward-Looking Statements

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

• Certain of our products are used by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment. Unforeseen adverse events, negative clinical outcomes, or increased regulatory scrutiny of these and their financial cost may damage public perception of the safety, utility, or efficacy of these vaccines and therapies or other modes of treatment and may harm our customers’ ability to conduct their business. Such events may negatively impact our revenue and have an adverse effect on our performance.
• We compete with life science, pharmaceutical and biotechnology companies who are substantially larger than we are and potentially capable of developing new approaches that could make our products, services and technology obsolete.
• We depend on a limited number of customers for a high percentage of our revenue. If we cannot maintain our current relationships with customers, fail to sustain recurring sources of revenue with our existing customers, or if we fail to enter into new relationships, our future operating results will be adversely affected.
• We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials and may not be able to find replacements or immediately transition to alternative suppliers.
• Such other factors as discussed throughout the “Risk Factors” section of our Annual Report on Form 10-K dated March 22, 2021 on file with the Securities and Exchange Commission.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

What is the significance of Maravai's recent stock offering on April 7, 2021?

Maravai's stock offering allows selling stockholders to liquidate shares, which can affect market perception.

How many shares of MRVI were offered in the public offering?

18,000,000 shares of MRVI were offered, an increase from earlier announcements.

What is the expected closing date for Maravai's stock offering?

The offering is expected to close on April 12, 2021.

Who are the underwriters for Maravai's stock offering?

Morgan Stanley, Jefferies, and Goldman Sachs are key underwriters for the offering.

Will Maravai receive proceeds from the stock offering?

No, Maravai will not receive any proceeds from the sale of shares by selling stockholders.